Our previous study showed that increased eosinophil proportion of ≥3.0% is an effective biomarker for predicting irAE occurrences in patients with renal cell carcinoma who received anti‐CTLA‐4 plus anti‐PD‐1 combination therapy.21 This evidence concerns the gene PDCD1 and hereditary clear cell renal cell carcinoma.